Inhibition Profiling of Retroviral Protease Inhibitors Using an HIV-2 Modular System
Viruses, 2015 Retroviral protease inhibitors (PIs) are fundamental pillars in the treatment of HIV infection and acquired immunodeficiency syndrome (AIDS). Currently used PIs are designed against HIV-1, and their effect on HIV-2 is understudied.
Mohamed Mahdi +3 more
doaj +1 more source
The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage? [PDF]
, 2011 Background: Although being considered as a rarely observed HIV-1 protease mutation in clinical isolates, the L76V-prevalence increased 1998-2008 in some European countries most likely due to the approval of Lopinavir, Amprenavir and Darunavir which can ...
Braun, Patrick +35 more
core +1 more source
A modular system to evaluate the efficacy of protease inhibitors against HIV-2.
PLoS ONE, 2014 The human immunodeficiency virus (HIV) protease is a homodimeric aspartyl protease that is crucial for the viral life-cycle, cleaving proviral polyproteins, hence creating mature protein components that are required for the formation of an infectious ...
Mohamed Mahdi +3 more
doaj +1 more source
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration [PDF]
, 2005 Background The genetic differences among HIV-1 subtypes may be critical to clinical management and drug resistance surveillance as antiretroviral treatment is expanded to regions of the world where diverse non-subtype-B viruses predominate.Methods and ...
Wynhoven, B +61 more
core +1 more source
Universitas Scientiarum, 2019 The HIV-1 protease plays an essential role in the replication cycle of HIV-1; therefore there is a direct need to develop novel inhibitors of the HIV-1 protease, which can cease the viral replication.
Ammara Akhtar, Waqar Hussain, Nouman Rasool3
doaj +1 more source
Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection [PDF]
, 2004 The initial virus strains from as many as 12% of individuals with primary human immunodeficiency virus (HIV) infection have a 50% inhibitory concentration less than or equal to0.4-fold that of HIV type 1(NL4-3) (HIV-1(NL4-3)) to ritonavir ...
Joseph B. Margolick +29 more
core +1 more source
A folding inhibitor of the HIV‐1 protease [PDF]
Proteins: Structure, Function, and Bioinformatics, 2005 AbstractBecause the human immunodeficiency virus type 1 protease (HIV‐1‐PR) is an essential enzyme in the viral life cycle, its inhibition can control AIDS. The folding of single‐domain proteins, like each of the monomers forming the HIV‐1‐PR homodimer, is controlled by local elementary structures (LES, folding units stabilized by strongly interacting,
R. A. Broglia +5 more
openaire +4 more sources
HIV-2 Protease resistance defined in yeast cells
Retrovirology, 2006 Background Inhibitors of the HIV-1 Protease currently used in therapeutic protocols, have been found to inhibit, although at higher concentrations, the HIV-2 encoded enzyme homologue.
Raoult Didier +3 more
doaj +1 more source
Mangiferin, an Anti-HIV-1 Agent Targeting Protease and Effective against Resistant Strains
Molecules, 2011 The anti-HIV-1 activity of mangiferin was evaluated. Mangiferin can inhibit HIV-1ⅢB induced syncytium formation at non-cytotoxic concentrations, with a 50% effective concentration (EC50) at 16.90 μM and a therapeutic index (TI) above 140. Mangiferin also
Rui-Rui Wang +6 more
doaj +1 more source
Viruses, 2022 Drug-resistance-associated mutation in essential proteins of the viral life cycle is a major concern in anti-retroviral therapy. M46I, a non-active site mutation in HIV-1 protease has been clinically associated with saquinavir resistance in HIV patients.
Nilottam Rana +8 more
doaj +1 more source